Search Results for “EC” – Page 71 – media

China Biopharm’s TQA3038 “siRNA” Phase I Clinic Completes Dosing in First Batch of Subjects

On December 5, China Biopharm announced that it is conducting a randomized, double-blind, placebo-controlled Phase I clinical trial to evaluate the safety, tolerability and pharmacokinetic profile of TQA3038, a small interfering RNA (siRNA) targeting the hepatitis B virus (HBV) developed independently by China Biopharm for the indication of chronic hepatitis B (CHB). TQA3038 is a small interfering RNA (siRNA) drug developed independently by China Biopharmaceuticals targeting HBV, with the indication of chronic hepatitis B. The first human clinical trial of TQA3038 has been completed with the enrollment of the first batch of subjects, and the dosing process went smoothly, and post-dosing observation has been completed. Chronic hepatitis B is a serious public health problem worldwide, with approximately 290 million chronically infected patients worldwide. China is a high prevalence area of hepatitis B. It is estimated that there are about 86 million chronic HBV-infected patients, and a large number of patients ...
- Source: drugdu
- 104
- December 12, 2023
BD receives 510(k) clearance for fingerstick blood test sample collection device

Dive Brief Becton Dickinson has received 510(k) clearance for a device that collects blood from a fingerstick instead of from the vein. The MiniDraw Capillary Blood Collection System container is slightly larger than its predicate device, the BD Microtainer MAP Microtube, but is cleared for sample collection in “ancillary healthcare facilities,” positioning BD and its partner Babson Diagnostics to support blood collection from community sites such as pharmacies. When Babson rolls out its BetterWay blood testing service next year, the device could support the collection of samples for lipid panel, selected chemistry tests, and hemoglobin and hematocrit analyses. Dive Insight BD began working with Babson to develop a capillary blood collection and testing system in 2019. The partners expanded their collaboration last year to support work on self-collection, mobile services and at-home collection. Devices that enable the collection of capillary, rather than venous, blood for tests of hemoglobin and hematocrit ...
- Source: drugdu
- 80
- December 12, 2023
Discovery of Rogue Protein Paves Way for Diagnostic Test to Detect Early-Onset Dementia

Neurodegenerative disorders are often marked by the buildup of amyloid filament inclusions of specific proteins in the brain. These proteins are critical in diagnosing and treating the associated diseases. Frontotemporal lobar degeneration (FTLD) is one such disorder, leading to frontotemporal dementia, which ranks just behind Alzheimer’s disease in prevalence. In about 10% of FTLD cases, the identity of the filament-forming protein was previously unknown. The protein FUS was the suspected culprit, given its presence in brain inclusions and its known genetic role in some instances of amyotrophic lateral sclerosis, another neurodegenerative condition. Now, researchers using electron cryo-microscopy have unexpectedly found that the filaments are instead formed by the protein TAF15. The research team from MRC Laboratory of Molecular Biology (Cambridge, UK) extracted amyloid filaments from the brains of four individuals affected by this type of FTLD. They carried out neuropathological examinations on the brain tissues obtained. Employing electron cryo-microscopy, they ...
- Source: drugdu
- 90
- December 12, 2023
Large language models enhance differential diagnosis, paving the way for AI-assisted medical decision-making

A recent study published in the ArXiv preprint* server discusses the optimization of large language models (LLMs) for accurate differential diagnosis (DDx). Background Accurate diagnosis is the first step in effective medical care. It has been perceived that artificial intelligence (AI)-based models can be used to assist clinicians for accurate diagnosis of a disease. The real-world diagnostic process involves an interactive and iterative process with rational reasoning about a DDx. A physician weighs different diagnostic possibilities based on varied clinical information procured from advanced diagnostic procedures. Deep learning has been applied to the generation of DDx in ophthalmology, dermatology, and radiology. Due to the absence of interactive capabilities, deep learning models cannot assist patients with diagnosis through fluent communication in their native language. This interactive shortcoming can be overcome with the development of LLMs, which can be used to design effective tools for DDx. LLMs are trained using a massive ...
- Source: drugdu
- 213
- December 9, 2023
Secretary of state sets out priorities for UK health and social care systems

The commitments will make health systems faster, simpler and fairer for patients Health and social care secretary Victoria Atkins has set out new priorities to improve the health and social care system in the UK. The new commitments intend to make the health and social care system faster, simpler and fairer for patients. As healthcare systems approach the winter season, Atkins has committed to ensuring that health and social care services are faster for patients by making it easier to get treatment locally, improving A&E performance and cutting waiting lists. She commits to making systems simpler for patients and staff with joined-up integrated care and reducing bureaucracy by giving them the latest technology to free up their time to care for patients. Furthermore, Atkins committed to making systems fairer by ensuring that children are protected from health harms; health outcomes are not determined by where people live; the government supports ...
- Source: drugdu
- 92
- December 9, 2023
Study reveals motor neuron region is affected in ALS

The neurological condition currently affects one in 300 people in the UK King’s College London (KCL) researchers have revealed a mechanism behind dysregulated neuronal activity, a key pathology of amyotrophic lateral sclerosis (ALS). The new study, published in Cell Reports, identifies the axon initial segment (AIS) as the region that drives abnormal regulation of neuronal activity in ALS. Affecting one in 300 people in the UK, ALS, or motor neurone disease, is a neurological disorder that progressively destroys neurons in the brain and spinal cord. Researchers found that the molecular, structural and functional changes in the AIS, the region where electrical signals in neurons initiate, cause abnormal neuronal excitability. In the study, researchers examined two of the most common genetic causes of AIS mutations in the genes, TDP-43 and C9ORF72. In ALS, the electrical signalling in motor neurons initially increases during the early stages of the condition and progressively becomes ...
- Source: drugdu
- 92
- December 9, 2023
AstraZeneca and generative AI company Absci enter $247m oncology partnership

AstraZeneca (AZ) and Absci have entered into a collaboration agreement worth up to $247m to develop an artificial intelligence (AI)-designed antibody drug for a specified oncology target. The partnership will combine AZ’s capabilities in oncology research and development with Absci’s Integrated Drug Creation platform, which the generative AI company says “unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimising multiple drug characteristics important to both development and therapeutic benefit”. The agreement includes an upfront commitment from AZ as well as research and development funding, milestone payments and royalties on product sales. Puja Sapra, senior vice president of biologics engineering and oncology targeted delivery at AZ, said: “This collaboration is an exciting opportunity to utilise Absci’s de novo AI antibody creation platform to design a potential new antibody therapy in oncology.” Absci outlines that its approach “overcomes the limits of traditional drug discovery”. ...
- Source: drugdu
- 120
- December 8, 2023
Intuitive’s venture capital arm launches second investment fund

Dive Brief Intuitive Surgical’s venture capital arm has launched a second investment fund with $150 million in new capital. The Intuitive Ventures fund will support startups focused on improving healthcare access and coordination, developing precision diagnostics and interventions, and integrating digital technology, the firm said Monday. The new fund follows the launch of Intuitive’s first venture capital fund three years ago and brings the firm’s total assets under management to $250 million. Dive Insight The robotic surgery leader is among a number of large medtech companies to establish a venture capital operation dedicated to supporting a portfolio of early-stage companies. GE HealthCare, Johnson & Johnson and Boston Scientific have also launched venture funds. The venture has since invested in more than 10 startups, supported by Intuitive Surgical’s network and corporate oversight. Those companies include Capstan Medical, Endogenex, Flywheel, KelaHealth, MedCrypt, Neocis Optellum and Surge Therapeutics. “Fund II deepens Intuitive’s commitment ...
- Source: drugdu
- 107
- December 7, 2023
Exactech wins clearance for new ankle surgery navigation system

BY CHRIS NEWMARKER ExactechGPS Ankle [Image courtesy of Exactech]Exactech announced today that its BlueOrtho subsidiary has received FDA 510(k) clearance for ExactechGPS Ankle. The Gainesville, Florida–based company described the system as the first of its kind for total ankle arthroplasty. It connects the preoperative plan with real-time intraoperative instrument guidance, confirming that resections meet the surgical plan. Designed to improve surgical precision, the ExactechGPS Ankle combines propriety active tracker technology with a touchscreen tablet, providing dynamic feedback to surgeons during procedures. “I am already a fan of Exactech’s patient-specific instrumentation solution and am thrilled how GPS Ankle provides intraoperative flexibility at my fingertips. The ability to quantify soft tissue laxity will be a game changer for me and my patients,” said design team surgeon Dr. Edward Haupt of the Mayo Clinic in Florida. GPS Ankle has compatibility with Exactech’s flagship Vantage Total Ankle System. It will be available to hospitals ...
- Source: drugdu
- 104
- December 7, 2023
As Stelara cliff looms, J&J expects 25 blockbuster drugs to drive future sales growth

As Johnson & Johnson places a magnifying glass on its pharmaceutical business, the focus for the remainder of the decade rests on the shoulders of some 25 new and upcoming drugs. Together, those meds will help the company deliver pharmaceutical sales growth of 5% to 7% between 2025 and 2030, the company said Tuesday. That phalanx of novel products will be essential as J&J’s longstanding immunology star, Stelara, nears its tumble over the patent cliff. Last year, the drug generated $9.7 billion and was J&J’s top product by sales. During an enterprise business review Tuesday, J&J laid out its expectations across the 2025 to 2030 timeframe. Chief among those, J&J says it will boast 10 or more drugs with peak sales potential of at least $5 billion, including cancer launches Talvey and Tecvayli, plus another 15-plus products with sales potential of at least $1 billion. The latter group of therapeutics ...
- Source: drugdu
- 92
- December 7, 2023

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.